Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study.
about
Cellular targeting in autoimmunityPolychromatic flow cytometry in evaluating rheumatic disease patientsThe rationale for BAFF inhibition in systemic lupus erythematosusDrugs derived from phage display: from candidate identification to clinical practiceA phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosusThe pathogenesis of systemic lupus erythematosus—an updateMycophenolic acid counteracts B cell proliferation and plasmablast formation in patients with systemic lupus erythematosusRationale for B cell targeting in SLEB-lymphocyte homeostasis and BLyS-directed immunotherapy in transplantation.BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus.Current and novel therapeutics in the treatment of systemic lupus erythematosusNo evidence that soluble TACI induces signalling via membrane-expressed BAFF and APRIL in myeloid cells.Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents.Dual B cell immunotherapy is superior to individual anti-CD20 depletion or BAFF blockade in murine models of spontaneous or accelerated lupus.Long-lived plasma cells are early and constantly generated in New Zealand Black/New Zealand White F1 mice and their therapeutic depletion requires a combined targeting of autoreactive plasma cells and their precursors.Efficacy of novel monoclonal antibody belimumab in the treatment of lupus nephritis.BAFF/APRIL inhibition decreases selection of naive but not antigen-induced autoreactive B cells in murine systemic lupus erythematosusB cells and autoimmunity.New treatment options for lupus - a focus on belimumab.Roles of pro- and anti-inflammatory cytokines in the pathogenesis of SLEMechanisms of B cell autoimmunity in SLE.Novel fusion proteins for the antigen-specific staining and elimination of B cell receptor-positive cell populations demonstrated by a tetanus toxoid fragment C (TTC) model antigen.Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosusLow numbers of blood and salivary natural killer cells are associated with a better response to belimumab in primary Sjögren's syndrome: results of the BELISS studyMolecular signature in HCV-positive lymphomasAdvances in human B cell phenotypic profiling.B-cell activating factor targeted therapy and lupus.Pathophysiological mechanisms in antiphospholipid syndromeTaming lupus-a new understanding of pathogenesis is leading to clinical advances.B-cell-depleting therapy in systemic lupus erythematosus.B cells as therapeutic targets in SLE.Therapeutic implications of advances in our understanding of transitional B-cell development in humans.Targeting BAFF in autoimmunity.Belimumab: a BLyS-specific inhibitor for systemic lupus erythematosus.Targeting B cells for the treatment of SLE: the beginning of the end or the end of the beginning?Long-lived autoreactive plasma cells drive persistent autoimmune inflammation.BAFF inhibition: a new class of drugs for the treatment of autoimmunity.An update on belimumab for the treatment of lupus.Clearing the complexity: immune complexes and their treatment in lupus nephritis.BAFF and selection of autoreactive B cells
P2860
Q26824580-88AD802A-198B-4365-90B1-3691554BAF24Q26827075-33F61822-9247-479C-8C3C-460688C3F40AQ26827373-DB59D310-A31D-490C-9291-9F590FBF395BQ27007101-0140D239-5D6E-4C33-A343-72E484C35866Q28254310-AE59E041-B00D-421D-BB50-4AA9B400919DQ29394347-10C2AE3C-A95F-4211-98C8-C52CE52264F2Q33766270-C63F0AB6-3AE6-4A5C-AB41-A326E7E90BBEQ33829700-45E9D695-0D7D-4E0C-A0AA-43BD533559C1Q34159016-EBD0B472-2F01-45C3-9A19-90B318F9F897Q34245983-C25196C8-2FA8-4717-97CD-E52E90DE8F15Q34648851-39607762-669F-4FCD-820C-1CCC5BD2ABEAQ34688769-3664BC80-C748-4AE3-826F-31D922372C0CQ34960458-BE0F81F1-DA28-40BF-962E-5D4C4E4658B3Q35035048-202F27DA-8575-42DF-A711-F66CFB6D9041Q35544326-4F0EEB6C-E0A8-4A72-B8A9-1256454F41C8Q35568194-BD1501F2-5468-43CC-A4C8-2DB3BB66E252Q35686772-BA7C8B6A-E311-452F-ADA2-09956EA12496Q35706966-D9E249E4-F41C-4A5E-8F59-27AB32E4C16BQ35752030-2181EDF1-32D1-4D72-9B1E-46A7B2E875B7Q35829864-8BAAEF94-B3D0-416E-8517-856F9E805E08Q35840704-3BCBA82A-D821-4BF4-9678-F78D25EAC87DQ35925459-2B5AE548-1140-489B-B8B1-0A638066F428Q35954719-FFCDAD17-4FA3-4789-A52E-607EBA1D1775Q36027561-9F9F925E-123A-4301-A50F-F2F834FE75E1Q36199986-EAC0E079-4AA8-4973-BC9A-A4FB9AEEC741Q36307080-F78E4967-98BF-4C16-98A2-B7124EB37E40Q36504641-03BE5DA4-2561-4FA8-ADD5-C5950358446EQ36671159-C826AA3C-CEA5-4748-8F61-E0F1B51B51A0Q36712941-A89B09C8-2DE1-4713-AD8F-817A501BB63CQ37586344-6DC9C8AE-221F-4467-A498-DD0D4CAA3CAAQ37603296-1A1F89A4-6DFA-4A6B-80C4-B5F655FF25F5Q37786629-26D11DD6-7D57-4F86-9A60-C6A876DC386CQ37802627-434357F9-F9C7-4790-8A40-143281BEB56BQ37809939-BCFAD3DD-8ED0-4919-AAA2-AD055DDD64CBQ37814530-50AFA777-1D7B-4A9F-8033-CE72DC3C6BDAQ37833902-127E9EBC-C8EF-47BF-A488-B98472EC1914Q37844764-6ECD5F82-ED49-4B41-A13A-4655FC5B269CQ37850690-A10E99CC-8F1F-4300-8CB7-0B9C8685A765Q37892917-5D358986-C52F-4E87-8839-26AF681B6614Q37900758-F5BFF0CF-898C-4EB8-84AF-DB65442D94CE
P2860
Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Effect of long-term belimumab ...... ontrolled, dose-ranging study.
@ast
Effect of long-term belimumab ...... ontrolled, dose-ranging study.
@en
type
label
Effect of long-term belimumab ...... ontrolled, dose-ranging study.
@ast
Effect of long-term belimumab ...... ontrolled, dose-ranging study.
@en
prefLabel
Effect of long-term belimumab ...... ontrolled, dose-ranging study.
@ast
Effect of long-term belimumab ...... ontrolled, dose-ranging study.
@en
P2093
P2860
P356
P1476
Effect of long-term belimumab ...... ontrolled, dose-ranging study.
@en
P2093
Annett M Jacobi
Betty Diamond
Cynthia Aranow
Inaki Sanz
Meggan Mackay
Richard Furie
Weiqing Huang
William Freimuth
P2860
P304
P356
10.1002/ART.27189
P577
2010-01-01T00:00:00Z